Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas
Sally F. Barrington, Regine Kluge
European Journal of Nuclear Medicine and Molecular Imaging (2017) Vol. 44, Iss. S1, pp. 97-110
Open Access | Times Cited: 241

Showing 1-25 of 241 citing articles:

EANM/EARL harmonization strategies in PET quantification: from daily practice to multicentre oncological studies
Nicolas Aide, Charline Lasnon, Patrick Veit‐Haibach, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2017) Vol. 44, Iss. S1, pp. 17-31
Open Access | Times Cited: 270
PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study
Olivier Casasnovas, Réda Bouabdallah, Pauline Brice, et al.
The Lancet Oncology (2019) Vol. 20, Iss. 2, pp. 202-215
Open Access | Times Cited: 185
Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial
Christine Mauz‐Körholz, Judith Landman‐Parker, Walentyna Balwierz, et al.
The Lancet Oncology (2021) Vol. 23, Iss. 1, pp. 125-137
Open Access | Times Cited: 108
FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma
Aaron C. Tan, Louise Emmett, Serigne Lo, et al.
Annals of Oncology (2018) Vol. 29, Iss. 10, pp. 2115-2120
Open Access | Times Cited: 140
Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Richard T. Hoppe, Ranjana H. Advani, Weiyun Z. Ai, et al.
Journal of the National Comprehensive Cancer Network (2020) Vol. 18, Iss. 6, pp. 755-781
Open Access | Times Cited: 130
How clinical imaging can assess cancer biology
Roberto García‐Figueiras, Sandra Baleato‐González, Anwar R. Padhani, et al.
Insights into Imaging (2019) Vol. 10, Iss. 1
Open Access | Times Cited: 111
Combination of baseline FDG PET/CT total metabolic tumour volume and gene expression profile have a robust predictive value in patients with diffuse large B-cell lymphoma
Mathieu Nessim Toledano, Paul Desbordes, Ayman Abdulhakim Banjar, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2018) Vol. 45, Iss. 5, pp. 680-688
Closed Access | Times Cited: 84
Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial
Heiko Schöder, Mei‐Yin C. Polley, Michael V. Knopp, et al.
Blood (2020) Vol. 135, Iss. 25, pp. 2224-2234
Open Access | Times Cited: 80
Baseline 18F-FDG PET radiomic features as predictors of 2-year event-free survival in diffuse large B cell lymphomas treated with immunochemotherapy
Nicolas Aide, Christophe Fruchart, Catherine Nganoa, et al.
European Radiology (2020) Vol. 30, Iss. 8, pp. 4623-4632
Closed Access | Times Cited: 74
PET/CT in Non-Hodgkin Lymphoma: An Update
Lucia Zanoni, Davide Bezzi, Cristina Nanni, et al.
Seminars in Nuclear Medicine (2022) Vol. 53, Iss. 3, pp. 320-351
Closed Access | Times Cited: 42
18F-FDG PET Maximum-Intensity Projections and Artificial Intelligence: A Win-Win Combination to Easily Measure Prognostic Biomarkers in DLBCL Patients
Kibrom Berihu Girum, Louis Rebaud, Anne‐Ségolène Cottereau, et al.
Journal of Nuclear Medicine (2022) Vol. 63, Iss. 12, pp. 1925-1932
Open Access | Times Cited: 38
PET-CT-guided characterisation of progressive, preclinical tuberculosis infection and its association with low-level circulating Mycobacterium tuberculosis DNA in household contacts in Leicester, UK: a prospective cohort study
Jee Whang Kim, Karen J. Bowman, Joshua Nazareth, et al.
The Lancet Microbe (2024) Vol. 5, Iss. 2, pp. e119-e130
Open Access | Times Cited: 8
Automated Lugano Metabolic Response Assessment in 18 F-Fluorodeoxyglucose–Avid Non-Hodgkin Lymphoma With Deep Learning on 18 F-Fluorodeoxyglucose–Positron Emission Tomography
Skander Jemaa, Souhila Ounadjela, Xiaoyong Wang, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 25, pp. 2966-2977
Open Access | Times Cited: 8
The role of PET/CT in the modern treatment of Hodgkin lymphoma
Jan Maciej Zaucha, Stéphane Chauvie, Renata Zaucha, et al.
Cancer Treatment Reviews (2019) Vol. 77, pp. 44-56
Closed Access | Times Cited: 66
The role of PET in the first-line treatment of the most common subtypes of non-Hodgkin lymphoma
Sally F. Barrington, Judith Trotman
The Lancet Haematology (2020) Vol. 8, Iss. 1, pp. e80-e93
Closed Access | Times Cited: 55
Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CT
Johannes Duell, Franziska Krummenast, Andreas Schirbel, et al.
Journal of Nuclear Medicine (2021) Vol. 62, Iss. 10, pp. 1415-1421
Open Access | Times Cited: 48
Why We Did What We Did: PSMA PET/CT Selection Criteria for the VISION Trial
Phillip H. Kuo, Taylor L. Benson, Richard A. Messmann, et al.
Journal of Nuclear Medicine (2022) Vol. 63, Iss. 6, pp. 816-818
Open Access | Times Cited: 37
Predictors and Real-World Use of Prostate-Specific Radioligand Therapy: PSMA and Beyond
Andrei Gafita, Charles Marcus, Louise Kostos, et al.
American Society of Clinical Oncology Educational Book (2022), Iss. 42, pp. 366-382
Open Access | Times Cited: 36
Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 1—Clinical)
Fabien Ricard, Bruce D. Cheson, Sally F. Barrington, et al.
Journal of Nuclear Medicine (2022) Vol. 64, Iss. 1, pp. 102-108
Open Access | Times Cited: 30
Stacking Ensemble Learning–Based [18F]FDG PET Radiomics for Outcome Prediction in Diffuse Large B-Cell Lymphoma
Shuilin Zhao, Jing Wang, Chentao Jin, et al.
Journal of Nuclear Medicine (2023) Vol. 64, Iss. 10, pp. 1603-1609
Open Access | Times Cited: 16
Positron Emission Tomography Score Has Greater Prognostic Significance Than Pretreatment Risk Stratification in Early-Stage Hodgkin Lymphoma in the UK RAPID Study
Sally F. Barrington, Elizabeth H. Phillips, Nicholas Counsell, et al.
Journal of Clinical Oncology (2019) Vol. 37, Iss. 20, pp. 1732-1741
Open Access | Times Cited: 53
[68Ga]Ga-Pentixafor PET/MRI for CXCR4 Imaging of Chronic Lymphocytic Leukemia
Marius E. Mayerhoefer, Ulrich Jaeger, Philipp B. Staber, et al.
Investigative Radiology (2018) Vol. 53, Iss. 7, pp. 403-408
Closed Access | Times Cited: 51
Assessing PET Parameters in Oncologic 18F-FDG Studies
İsmet Sarikaya, Ali Sarıkaya
Journal of Nuclear Medicine Technology (2019) Vol. 48, Iss. 3, pp. 278-282
Open Access | Times Cited: 46
Impact of acquisition time and penalizing factor in a block-sequential regularized expectation maximization reconstruction algorithm on a Si-photomultiplier-based PET-CT system for 18F-FDG
Elin Trägårdh, David Minarik, Helén Almquist, et al.
EJNMMI Research (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 44
Just another “Clever Hans”? Neural networks and FDG PET-CT to predict the outcome of patients with breast cancer
Manuel Weber, David Kersting, Lale Umutlu, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2021) Vol. 48, Iss. 10, pp. 3141-3150
Open Access | Times Cited: 34
Page 1 - Next Page

Scroll to top